Posted incompare
A 26-Week Randomized Open-Label Trial Compared Liraglutide Once Daily to Exenatide Twice Daily in Type 2 Diabetes
Liraglutide, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, was compared to twice-daily exenatide in a 26-week randomized, open-label trial involving adults with inadequately controlled type 2 diabetes. This study evaluated…